Insider · CIK 0001378166

Young David

Reports to the SEC for 2 companies · VERO BEACH, FL

sec.gov

Transactions

Companies

Filings

CIK

0001378166

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-30	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+2,531 sh	$1.93	+$4,884.83	21,729
2026-06-15	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+2,067 sh	$2.22	+$4,588.74	19,198
2026-05-29	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+1,786 sh	$2.57	+$4,590.02	17,131
2026-05-15	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+1,545 sh	$2.97	+$4,588.65	15,345
2026-04-30	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+1,706 sh	$2.69	+$4,589.14	13,813
2026-04-15	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+1,545 sh	$2.97	+$4,588.65	12,107
2026-03-31	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+1,810 sh	$2.54	+$4,588.35	10,562
2026-01-01	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	+49 sh	—	—	8,752
2026-01-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	−49 sh	—	—	0
2025-10-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+111K sh	—	—	111,000
2025-10-01	PCSAProcessa Pharmaceuticals, Inc. · Stock Options (Right to Buy)A Award	Director, Pres. Research & Development	AAward	+333K sh	—	—	333,000
2025-07-24	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+1.81M sh	—	—	1,821,016
2025-04-01	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	+17.3K sh	—	—	222,677
2025-04-01	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Director, Pres. Research & Development	FTax Payment	−5,345 sh	$0.41	−$2,202.14	217,332
2025-01-29	PCSAProcessa Pharmaceuticals, Inc. · WarrantsA Award	Director, Pres. Research & Development	AAward	+125K sh	—	—	124,500
2025-01-29	PCSAProcessa Pharmaceuticals, Inc. · WarrantsA Award	Director, Pres. Research & Development	AAward	+62.3K sh	—	—	62,250
2025-01-27	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+125K sh	$0.80	+$99.3K	205,405
2024-07-10	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	+644 sh	—	—	81,187
2024-07-10	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Director, Pres. Research & Development	FTax Payment	−282 sh	$1.71	−$482.22	80,905
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+3,233 sh	—	—	21,922
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+2,425 sh	—	—	24,347
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+404 sh	—	—	24,751
2024-06-28	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+404 sh	—	—	25,155
2024-04-05	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	+1,675 sh	—	—	81,061
2024-04-05	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Director, Pres. Research & Development	FTax Payment	−518 sh	$2.79	−$1,445.22	80,543
2024-02-07	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+21K sh	$2.45	+$51.5K	79,387
2024-02-06	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+20K sh	$2.53	+$50.5K	58,387
2024-01-01	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	+1,675 sh	—	—	81,062
2024-01-01	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Director, Pres. Research & Development	FTax Payment	−518 sh	$2.79	−$1,445.22	80,544
2024-01-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	−1,675 sh	—	—	19,333
2023-10-12	PCSAProcessa Pharmaceuticals, Inc.A Award	Director, Pres. Research & Development	AAward	+155K sh	$0.29	+$45K	767,701
2023-10-10	PCSAProcessa Pharmaceuticals, Inc.A Award	Director, Pres. Research & Development	AAward	+142K sh	$0.24	+$34.1K	612,424
2023-06-12	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+40K sh	$0.80	+$32K	470,424
2023-04-14	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+20K sh	$0.55	+$11K	430,424
2023-04-13	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+20K sh	$0.48	+$9,600	410,424
2023-04-12	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+20K sh	$0.45	+$9,000	390,424
2023-04-11	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director, Pres. Research & Development	PPurchase	+20K sh	$0.52	+$10.4K	370,424
2023-02-09	PCSAProcessa Pharmaceuticals, Inc.A Award	Director, Pres. Research & Development	AAward	+18.8K sh	$0.80	+$15K	350,424
2023-01-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+24K sh	—	—	424,373
2022-12-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+25.4K sh	—	—	400,343
2022-09-30	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+25.4K sh	—	—	374,993
2022-08-16	PCSAProcessa Pharmaceuticals, Inc.G Gift	Director, Pres. Research & Development	GGift	−9,250 sh	—	—	377,784
2022-08-05	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director, Pres. Research & Development	MExercise/Conversion	+7,601 sh	—	—	389,565
2022-08-05	PCSAProcessa Pharmaceuticals, Inc.F Tax Payment	Director, Pres. Research & Development	FTax Payment	−2,531 sh	$3.17	−$8,023.27	387,034
2022-06-30	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+46.9K sh	—	—	349,643
2022-04-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+248K sh	—	—	302,766
2022-03-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+10.7K sh	—	—	37,781
2021-12-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+6,722 sh	—	—	22,780
2021-12-31	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+6,722 sh	—	—	6,722
2021-11-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director, Pres. Research & Development	AAward	+4,286 sh	—	—	27,066

Recent filings

Accepted (ET)
Jul 14
Young David0000897069-26-001476
SEC(opens sec.gov)
Jun 164
Young David0000897069-26-001414
SEC(opens sec.gov)
Jun 14
Young David0000897069-26-001295
SEC(opens sec.gov)
May 194
Young David0000897069-26-001184
SEC(opens sec.gov)
May 14
Young David0000897069-26-001010
SEC(opens sec.gov)
Apr 174
Young David0000897069-26-000912
SEC(opens sec.gov)
Apr 14
Young David0000897069-26-000756
SEC(opens sec.gov)
Feb 44
Young David0000897069-26-000224
SEC(opens sec.gov)
Oct 34
Young David0000897069-25-001545
SEC(opens sec.gov)
Jul 284
Young David0000897069-25-001215
SEC(opens sec.gov)
Apr 114
Young David0000897069-25-000787
SEC(opens sec.gov)
Feb 184/A
Young David0000897069-25-000294
SEC(opens sec.gov)
Jan 294
Young David0000897069-25-000132
SEC(opens sec.gov)
Aug 24
Young David0000897069-24-001606
SEC(opens sec.gov)

Companies

Address

C/O PROCESSA PHARMACEUTICALS, INC. 601 21ST STREET SUITE 300

VERO BEACH, FL, 32960